SLC22A16 and breast cancer: The results suggest that the risk of death, disease progression or recurrence of breast cancer is modified by genetic variants of nuclear receptors (NR1/2, PGR), genes engaged in main metabolic pathway of doxorubicin (SLC22A16) and doxorubicin-progesterone-related gene (AKR1C3).